Page last updated: 2024-09-02

ecteinascidin 743 and Genital Neoplasms, Female

ecteinascidin 743 has been researched along with Genital Neoplasms, Female in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Aissaoui, D; Essafi-Benkhadir, K; Souid, S; Srairi-Abid, N1
Kim, HJ; Kim, JW; Kim, M; Lee, KH; Suh, DH1

Reviews

2 review(s) available for ecteinascidin 743 and Genital Neoplasms, Female

ArticleYear
Trabectedin (Yondelis®) as a Therapeutic Option in Gynecological Cancers: A Focus on its Mechanisms of Action, Clinical Activity and Genomic Predictors of Drug Response.
    Current drug targets, 2020, Volume: 21, Issue:10

    Topics: Antineoplastic Agents, Alkylating; Biomarkers, Pharmacological; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Female; Genital Neoplasms, Female; Genomics; Humans; Trabectedin

2020
Major clinical research advances in gynecologic cancer in 2015.
    Journal of gynecologic oncology, 2016, Volume: 27, Issue:6

    Topics: Biomedical Research; Breast Neoplasms; Combined Modality Therapy; Dioxoles; Endometrial Neoplasms; Female; Genital Neoplasms, Female; Humans; Immunotherapy; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Papillomavirus Vaccines; Precision Medicine; Tetrahydroisoquinolines; Trabectedin; Uterine Cervical Neoplasms; Uterine Neoplasms

2016